LDS/Medical Tests/Lymphocyte proliferation panel, Blood

Lymphocyte proliferation panel, Blood

While monitoring absolute lymphocyte counts is useful in disease diagnosis, evaluating the functional capacity of these cells is equally important. Functional lymphocyte assessment determines whether T-cells can proliferate adequately upon stimulation, which is a vital indicator of robust immune function. The lymphocyte proliferation panel evaluates T-cell responsiveness to two main types of stimuli:

  • Mitogens: Non-specific plant lectins (e.g., phytohemagglutinin [PHA], concanavalin A [ConA], pokeweed mitogen [PWM]) that strongly stimulate lymphocytes regardless of prior antigen exposure.
  • Antigens: Specific proteins such as tetanus toxoid, tuberculin purified protein derivative (PPD), and Candida albicans, which assess antigen-specific cellular memory responses.

This assessment involves isolating T-cells from peripheral blood via density gradient separation (typically Ficoll-Paque), then exposing them to the selected stimuli in vitro. After 3–7 days of incubation, T-cell proliferation is quantified using various methods, such as radioactive thymidine (3H-thymidine) incorporation, ATP-based bioluminescence assays, or flow cytometry assays utilizing carboxyfluorescein succinimidyl ester (CFSE) or bromodeoxyuridine (BrdU) to measure cellular proliferation and DNA synthesis. Lymphopenia (low T-cell counts) can artificially lower observed proliferation. However, flow cytometry analysis compensates for this effect by precisely identifying proliferating cell populations.

  • Diagnosing immunodeficiency disorders due to impaired T-cell function (e.g., SCID, DiGeorge syndrome, HIV/AIDS)
  • Evaluating and monitoring T-cell function in patients undergoing immunosuppressive therapy, including transplant recipients, autoimmune patients, and oncology patients receiving chemotherapy

Increased proliferation:

  • Autoimmune diseases
  • Lymphoproliferative disorders
  • Chronic inflammatory conditions
  • Allergic reactions and drug hypersensitivities

Decreased proliferation:

  • Primary T-cell immunodeficiency
  • HIV/AIDS
  • Post-chemotherapy
  • Post immunosuppressive therapy
  • Malnutrition
  • Chronic infections from TB or EBV
  • High-dose or long term low-dose corticosteroid therapy
Parameter Reference Value
Viability of lymphocytes (Day 0) ≥75.0%

 

Maximum Proliferation of Phytohemagglutinin (PHA) Reference Value
% CD45-positive cells ≥49.9%
% CD3-positive cells ≥58.5%

 

Maximum Proliferation of Pokeweed Mitogen (PWM) Reference Value
% CD45-positive cells ≥4.5%
% CD3-positive cells ≥3.5%
% CD19-positive cells ≥3.9%
Flow cytometry-based lymphocyte proliferation assay.

Whole blood, sodium heparin (Green) vial, blood filled up to the black label on the vial, 20mL blood required which approximates 5 vials.

Stability

  • Ambient: 48 hours
  • Refrigerated: Unacceptable
  • Frozen: Unacceptable
Common Variable Immunodeficiency Panel, Severe Combined Immunodeficiency Panel by Next-Generation Sequencing (NGS), T-Cell Receptor, Excision Circles (TRECs), Immunoglobulin Levels (IgG, IgA, IgM, IgE), Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP), IgG Subclasses, 22q11.2 Deletion/Duplication Testing, CD4/CD8 Lymphocyte Ratio, Serum Protein Electrophoresis (SPEP).
1 – 2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login